APA (7th ed.) Citation

Goldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R., Nievergall, E., Tichy, D., . . . Weisel, K. C. (2022). Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. The lancet. Haematology, 9(11), . https://doi.org/10.1016/S2352-3026(22)00263-0

Chicago Style (17th ed.) Citation

Goldschmidt, Hartmut, et al. "Addition of Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Newly Diagnosed, Transplantation-eligible Patients with Multiple Myeloma (GMMG-HD7): Part 1 of an Open-label, Multicentre, Randomised, Active-controlled, Phase 3 Trial." The Lancet. Haematology 9, no. 11 (2022). https://doi.org/10.1016/S2352-3026(22)00263-0.

MLA (9th ed.) Citation

Goldschmidt, Hartmut, et al. "Addition of Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Newly Diagnosed, Transplantation-eligible Patients with Multiple Myeloma (GMMG-HD7): Part 1 of an Open-label, Multicentre, Randomised, Active-controlled, Phase 3 Trial." The Lancet. Haematology, vol. 9, no. 11, 2022, https://doi.org/10.1016/S2352-3026(22)00263-0.